Orforglipron for Obesity

Recruiting in Palo Alto (17 mi)

+29 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Eli Lilly and Company

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

This trial is for individuals who are overweight or have obesity with related health issues. It's designed to see if they can maintain weight loss after initial reduction. Specific eligibility details aren't provided, but typically participants must meet certain health criteria and not be taking conflicting medications.

Inclusion Criteria

Have completed the SURMOUNT-5 study on study treatment

Exclusion Criteria

I have hepatitis.

I have a history of pancreatitis.

I have a history of diabetes or severe diabetic complications.

See 1 more

Treatment Details

Interventions

Orforglipron (Other)

Trial OverviewThe study is testing the effectiveness of a drug called Orforglipron in helping people keep off weight they've already lost. Participants will either receive Orforglipron or a placebo (a substance with no active drug) to compare results.

Participant Groups

2Treatment groups

Experimental Treatment

Placebo Group

Group I: OrforglipronExperimental Treatment1 Intervention

Participants will receive orforglipron orally

Group II: PlaceboPlacebo Group1 Intervention

Participants will receive placebo orally